PDE4D and Alzheimer disease: The pyridine-based Zatomilast (Table 3) proved to be a negative allosteric modulator of the PDE4D enzyme (IC50 = 8 nM) and has been evaluated in two clinical trials for the treatment of AD and FXS [91].